Amarillo Biosciences, Inc. (ABI) is a diversified healthcare company engaged in the discovery and development of pharmaceutical and biotech products. Our goal is to introduce novel products that actively stimulate and rejuvenate the human body to combat disease and enhance the ability to heal. We engage in the advancement of low-dose non-injectable interferon as a therapeutic treatment for numerous indications such as thrombocytopenia, Sjögren’s syndrome, hepatitis C virus (HCV) and influenza. ABI primarily operates through three divisions: Pharmaceutical, Medical and Consumer. The Pharmaceutical division leverages a proprietary library of over a hundred scientific and clinical data studies on various human and animal applications of low-dose interferon, for patent licensing and commercialization opportunities with global partners. The Medical division is focused on developing an innovative, state-of-the-art technology to treat metabolism related diseases such as Type 1 and Type 2 diabetes in Asia. The Consumer division includes a range of nutraceutical and food supplement products that utilize our unique liposomal delivery systems. ABI currently has offices in the United States and Taiwan.
Company profile
Ticker
AIMD
Exchange
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
AMARILLO BIOSCIENCES INC
SEC CIK
Corporate docs
IRS number
751974352
AIMD stock data
Investment data
Securities sold
Number of investors
Calendar
16 May 22
9 Aug 22
31 Dec 22
Financial summary
| Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.87M | 1.87M | 1.87M | 1.87M | 1.87M | 1.87M |
| Cash burn (monthly) | (no burn) | (no burn) | 694.35K | 132.79K | 463.3K | 202.34K |
| Cash used (since last report) | n/a | n/a | 2.99M | 571.78K | 1.99M | 871.25K |
| Cash remaining | n/a | n/a | -1.12M | 1.3M | -123.51K | 1M |
| Runway (months of cash) | n/a | n/a | -1.6 | 9.8 | -0.3 | 4.9 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 28 Jul 22 | Hui-Lan Wu | RSU Common Stock | Grant | Acquire A | No | No | 0 | 2,000,000 | 0 | 2,000,000 |
| 28 Jul 22 | chun-hsien tsai | RSU Common Stock | Grant | Acquire A | No | No | 0 | 5,000,000 | 0 | 5,000,000 |
| 28 Jul 22 | chung-yi tsai | RSU Common Stock | Grant | Acquire A | No | No | 0 | 330,000 | 0 | 330,000 |
| 28 Jul 22 | yao-chung chiang | RSU Common Stock | Grant | Acquire A | No | No | 0 | 330,000 | 0 | 330,000 |
| 28 Jul 22 | wen-han chang | RSU Common Stock | Grant | Acquire A | No | No | 0 | 330,000 | 0 | 330,000 |
| 31 Mar 22 | Hui-Lan Wu | Convertible Note Common Stock | Grant | Acquire A | Yes | No | 1 | 50,000 | 50K | 50,000 |
Institutional ownership, Q3 2021
69.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 1 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 50M |
| Total shares | 100M |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Ainos | 100M | $50M |
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
acid, acquisition, adjustment, aka, APA, Attorney, automatically, borrowing, Calibre, Chain, CICCT, collaboration, collaborator, concentrated, correct, covid, cumulative, daughter, default, delegating, delegation, depreciation, diversification, draft, driven, duty, edgar, eighty, enumerated, EUA, exhaust, fail, female, Footnote, forecast, foresee, GAAP, grew, guarantee, harbor, hereof, holder, Hsu, implied, imprecise, incorrect, InnoPharmax, IP, IXBRL, Liao, met, modified, narrative, noninterest, notice, nucleic, obligation, offset, outlook, Oxley, parallel, pathway, percent, Polymerase, preferred, prioritizing, publicly, RBD, Reaction, recruit, Reform, remediate, remediation, repaid, repayment, seamlessly, sooner, Taiwanese, threshold, Top, turn, unforeseen, unknown, upcoming, version, Virgin, worse
Removed:
abroad, academic, accurately, achieving, acquire, activation, actively, advancing, advantage, advertising, Advisor, affecting, alternative, Alternatively, amendment, animal, antitrust, applicant, applying, appointed, approximately, Asia, assessing, assist, assure, attached, attestation, bacterial, begin, beneficial, Bernard, biotech, biotechnology, branch, cancer, candidate, canker, carefully, cell, CFR, Chairman, characterized, chemically, Chen, china, choose, Chrystal, civil, claimed, classified, cleared, climate, closely, Cohen, commence, compare, compete, competition, competitive, complex, complexity, comply, composition, comprehensive, consultant, consummation, content, continually, convey, corrupt, Cosmetic, costly, country, criminal, cultural, currency, custom, cytotoxic, damage, deficit, define, delivery, demonstrate, demonstration, designation, determined, developed, diagnostic, difficult, difficulty, digital, diminish, discovery, discussed, disruption, distance, distributing, diversion, division, Documented, Dr, economic, economically, effect, efficacy, enacted, enforcement, engineered, enhance, environment, equivalence, Esq, established, ethical, evaluating, evolving, exceed, exempt, expanding, experience, experienced, Expiration, explore, exploring, export, expose, fabrication, face, facilitate, facility, Failure, feasible, fewer, firm, focusing, food, foreign, formal, forward, framework, gain, genetically, genital, Geographic, geopolitical, global, govern, governing, governmental, grant, greater, greatly, group, hardware, healthy, helicobacter, hereto, high, human, identify, iii, imitate, immune, impairment, impede, importance, improved, inability, IND, independent, industry, infection, influenza, informal, infusion, inherently, injury, innovative, inspection, insulin, insure, integrated, intelligence, intense, intravenously, invention, investigational, John, judgment, judiciously, June, Junyong, labeling, labor, laboratory, lack, language, large, Lawrence, legally, legislative, level, leverage, library, licensing, life, likelihood, limit, limited, Lin, LLC, local, location, longer, lower, manager, managing, manner, marketed, matter, media, metabolic, method, model, monetary, month, monthly, nationalization, natural, nature, NDA, negatively, newer, nutraceutical, obtained, October, offered, operate, operated, operational, opposed, orphan, ownership, patent, path, pending, performed, permit, person, physical, PMA, political, precedent, predecessor, predicate, premarket, present, presently, prevent, preventing, pricing, privacy, Procuring, produce, producer, production, prohibiting, promoting, promotion, promulgated, proposed, publicity, pulsatile, pump, pursuing, pylori, quality, rapidly, rare, recapitalization, received, recognize, record, recoup, registered, regularly, regulate, regulated, reimbursement, repatriation, reputation, require, resource, restoration, restricted, restrictive, retained, rigidity, risky, role, route, safety, satisfy, satisfying, scaling, scientific, scientifically, scope, Secretary, secure, selected, September, serve, service, Shelton, shorten, shorter, situation, smart, software, source, sourcing, Sponsoring, state, steadily, Stephen, stockholder, storage, strain, Submission, submit, succeed, superiority, supplement, supply, synthesized, system, technical, technological, temporary, terminated, terrorism, threatened, timeframe, trade, traditional, Treadway, treat, typical, unanticipated, undergo, Unfavorable, unique, United, unpredictable, unreasonable, unsuccessful, utility, utilize, variety, vary, varying, volume, war, wide, worked, workforce, written
Current reports
8-K
Departure of Directors or Certain Officers
24 Jun 22
8-K/A
Departure of Directors or Certain Officers
17 Jun 22
8-K
Departure of Directors or Certain Officers
16 Jun 22
8-K
Entry into a Material Definitive Agreement
15 Apr 22
8-K
Entry into a Material Definitive Agreement
4 Apr 22
8-K
Entry into a Material Definitive Agreement
17 Mar 22
8-K
Entry into a Material Definitive Agreement
3 Feb 22
8-K
Entry into a Material Definitive Agreement
29 Dec 21
8-K
Ainos Announces Strategic Relationship with InnoPharmax to Jointly Develop Combined Oral Therapy for Coronavirus Infection
8 Dec 21
8-K
Entry into a Material Definitive Agreement
22 Nov 21
Registration and prospectus
8-A12B
Registration of securities on exchange
1 Aug 22
S-1/A
IPO registration (amended)
8 Jul 22
S-8
Registration of securities for employees
7 Jul 22
S-8
Registration of securities for employees
7 Jul 22
S-1
IPO registration
28 Apr 22
D
$20M in equity, sold $20M
3 May 21
D/A
$30M in equity, sold $721.03K, 10 investors
28 Aug 18
Other
EFFECT
Notice of effectiveness
9 Aug 22
CERT
Certification of approval for exchange listing
8 Aug 22
UPLOAD
Letter from SEC
18 Mar 21
CORRESP
Correspondence with SEC
16 Feb 21
UPLOAD
Letter from SEC
14 Feb 21
EFFECT
Notice of effectiveness
20 Jun 11
EFFECT
Notice of effectiveness
27 Mar 11
CORRESP
Correspondence with SEC
24 Mar 11
CORRESP
Correspondence with SEC
27 Feb 11
UPLOAD
Letter from SEC
10 Feb 11
Ownership
4
Ainos / PAO-SHENG WEI ownership change
29 Jul 22
4
Ainos / chung-yi tsai ownership change
29 Jul 22
4
Ainos / yao-chung chiang ownership change
29 Jul 22
4
Ainos / wen-han chang ownership change
29 Jul 22
4
Ainos / chun-hsien tsai ownership change
28 Jul 22
4
Ainos / Hui-Lan Wu ownership change
28 Jul 22
3
Ainos / PAO-SHENG WEI ownership change
30 Jun 22
4
Ainos / STEPHEN T CHEN ownership change
27 Jun 22
4
Change in insider ownership
6 May 22
4/A
Ainos / Hui-Lan Wu ownership change
13 Apr 22